Financial Data and Key Metrics Changes - The company reported a consolidated GAAP net loss of $51 million or a negative $1.01 per share for Q4 2025, compared to a consolidated GAAP net loss of $51 million or a negative $1.07 per share for Q4 2024 [13] - For the full year 2025, the consolidated GAAP net loss was $177 million or a negative $3.58 per share, an improvement from a consolidated net loss of $447 million or a negative $9.43 per share for 2024 [15] - The adjusted net income for full year 2025 was $23 million or $0.46 per share, compared to an adjusted net loss of $184 million or a negative $3.90 per share for 2024 [17] Business Line Data and Key Metrics Changes - National reported a statutory net income of $5 million for Q4 2025, compared to a statutory net loss of $10 million for Q4 2024 [20] - For the full year 2025, National reported a statutory net income of $88 million, compared to a statutory net loss of $133 million for 2024 [20] - MBIA Insurance Corp. reported a statutory net loss of $7 million for Q4 2025, compared to statutory net income of $4 million for Q4 2024 [22] Market Data and Key Metrics Changes - The gross par amount outstanding for National's insured portfolio declined by approximately $3 billion from year-end 2024 to about $22 billion at the end of 2025 [11] - MBIA Insurance Corp.'s insured gross par outstanding was approximately $2 billion as of December 31, 2025, down about 13% from year-end 2024 [23] Company Strategy and Development Direction - The company continues to prioritize resolving National's PREPA exposure, with a focus on reducing legal issues related to the Financial Oversight and Management Board [10] - The management is exploring options for a potential sale of the company or its components, emphasizing that all options are on the table for maximizing shareholder value [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about potential developments in the PREPA restructuring process, although no substantive progress has been made recently [10] - The company is in regular discussions with regulators regarding special dividends and is assessing the timing based on portfolio runoff and PREPA exposure reduction [61] Other Important Information - As of December 31, 2025, National had total claims-paying resources of $1.4 billion and statutory capital surplus in excess of $900 million [12] - MBIA Inc.'s book value per share decreased to a negative $44.27 as of December 31, 2025, primarily due to the consolidated net loss for the year [18] Q&A Session Summary Question: Did the company explore the potential for a special dividend in Q4 2025? - Management indicated that while there is no specific information at this time, they are continuously evaluating the possibility of a special dividend as circumstances improve [26][27] Question: What is the latest update on the strategic process regarding a potential sale of the company? - Management stated that all options are being considered, including selling the entire company or just National, depending on what is best for shareholders [28][30] Question: Is there a bid to sell the rest of the PREPA exposure? - Management clarified that there is limited exposure left and that the remaining $425 million cannot be sold in the same manner as previous transactions [33][36] Question: Are there pressures from auditors regarding higher valuation reserves related to non-Puerto Rican credits? - Management confirmed that they are comfortable with the current portfolio and have not identified any specific credits requiring additional reserves [41] Question: What needs to happen for MBIA Insurance to wrap up its operations? - Management noted that the runoff is proceeding as expected, and once the major restructuring related to Zohar is resolved, there may be opportunities to accelerate the runoff of MBIA Insurance Corp. [45][47]

Core Insights - Warner Bros. Discovery (WBD) experienced a mixed third quarter, with significant hits in film but declining advertising revenue, reinforcing the rationale for a potential sale or split of its business segments [1][5]. Financial Performance - Consolidated revenue decreased by 16% to $1.4 billion, missing Wall Street expectations, and the company reported a net loss of $148 million. Adjusted earnings rose by 2% to $2.5 billion, with $1.3 billion in restructuring expenses and one-time charges [1]. - Advertising revenue fell by 16% to $1.4 billion, impacted by tough comparisons with the previous year due to the Summer Olympic Games and a decline in domestic pay TV subscribers [3]. Theatrical and Streaming Performance - Theatrical revenue surged by 74%, contributing to a 23% increase in studio revenue to $3.3 billion. Notable film performances included DC's Superman grossing $615 million, Weapons exceeding $267 million, and The Conjuring: Last Rites surpassing $490 million [2]. - HBO Max added 2.3 million subscribers, reaching a total of 128 million, with streaming revenue remaining flat at $2.6 billion and profit increasing by 19% to $345 million [4]. Strategic Moves - WBD announced plans to split its businesses but has also received multiple bids for acquisition, including a recent offer of $23.50 from David Ellison, the new owner of Paramount. The company is exploring offers for both the entire business and its individual segments [5][6]. - The company aims to finalize any potential transactions by year-end; if unsuccessful, it plans to proceed with the split of its studio and streaming operations from linear television by mid-2026 [6].

Core Viewpoint - Warner Bros Discovery is exploring the possibility of an outright sale due to interest from multiple potential buyers, while simultaneously proceeding with its planned split into two separate companies [1] Group 1 - The company is considering a full sale as a strategic option amidst interest from various buyers [1] - Warner Bros Discovery is moving forward with its previously announced plan to split into two distinct entities [1]

Core Viewpoint - Shah Capital has called on Novavax's board to consider selling the biotech company due to a third consecutive year of poor performance in the rollout of its COVID-19 vaccine [1] Company Summary - Novavax has faced challenges in effectively distributing its COVID-19 vaccine for three years in a row, prompting concerns from investors [1]